Author:
Xu Nani,Xu Yu,Dai Rongrong,Zheng Lin,Qin Pan,Wan Peng,Yang Yejing,Jiang Jianmin,Zhang Hangjie,Hu Xiaowei,Lv Huakun
Abstract
IntroductionChina experienced a record surge of coronavirus disease 2019 cases in December 2022, during the pandemic.MethodsWe conducted a randomized, parallel-controlled prospective cohort study to evaluate efficacy and antibody duration after a fourth-dose booster with Ad5-nCoV or inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.ResultsA total of 191 participants aged ≥18 years who had completed a three-dose regimen of the inactivated SARS-CoV-2 vaccine 6 months earlier were recruited to receive the intramuscular Ad5-nCoV booster or the inactivated SARS-CoV-2 vaccine. The Ad5-nCoV group had significantly higher antibody levels compared with the inactivated vaccine group at 6 months after the fourth vaccination dose. After the pandemic, the breakthrough infection rate for the Ad5-nCoV and the inactivated vaccine groups was 77.89% and 78.13%, respectively. Survival curve analysis (p = 0.872) and multivariable logistic regression analysis (p = 0.956) showed no statistically significant differences in breakthrough infection between the two groups.DiscussionCompared with a homologous fourth dose, a heterologous fourth dose of Ad5-nCoV elicited a higher immunogenic response in healthy adults who had been immunized with three doses of inactivated vaccine. Nevertheless, the efficacy of the two vaccine types was equivalent after the pandemic.
Subject
Immunology,Immunology and Allergy
Reference36 articles.
1. Statement on the second meeting of the international health regulations (2005) emergency committee regarding the outbreak of novel coronavirus (2019-nCoV).2020
2. 2023
3. Statement on the fourteenth meeting of the international health regulations (2005) emergency committee regarding the coronavirus disease (COVID-19) pandemic.2023
4. Covid-19 vaccine effectiveness against symptomatic sars-Cov-2 infection during delta-dominant and omicron-dominant periods in japan: A multi-center prospective case-control study (Fascinate study);Arashiro;Clin Infect Dis,2022
5. Vaccine effectiveness against sars-Cov-2 infection or covid-19 hospitalization with the alpha, delta, or omicron sars-Cov-2 variant: A nationwide danish cohort study;Gram;PloS Med,2022